Earnings Call Summary | Agile Therapeutics(AGRX.US) Q4 2023 Earnings Conference
Earnings Call Summary | Agile Therapeutics(AGRX.US) Q4 2023 Earnings Conference
The following is a summary of the Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript:
以下是敏捷療法公司（AGRX）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Agile Therapeutics reported a full year net revenue of $19.6 million in 2023, an 80% increase from the prior year.
The company successfully decreased operating expenses to $30.5 million, representing a 33% decrease from 2022.
In Q4 2023, Agile reported a 46% decrease in net revenue compared to the previous quarter, leading to revenue of $3.6 million.
敏捷療法報告稱，2023年全年淨收入爲1,960萬美元，比上年增長80％。
該公司成功地將運營支出減少至3,050萬美元，比2022年下降了33％。
2023年第四季度，敏捷報告淨收入與上一季度相比下降了46％，收入爲360萬美元。
Business Progress:
業務進展：
The company noticed substantial year-over-year growth with the demand and sales of Twirla, alongside a reduction in operating expenses in 2023.
Early performance in 2024 indicates a valuable recovery with Twirla demand at its peak since launch.
Agile has cleared its debt to Perceptive Advisors, subsequently increasing its financial flexibility for forthcoming opportunities.
Despite receiving a delisting notice from Nasdaq, Agile's stock remains active on the OTC market.
Any changes to the Affordable Care Act could enhance access for roughly 49 million women to no-cost contraceptive products such as Twirla.
Agile continues to explore opportunities for financing options and strategic partnerships to drive further business growth.
該公司注意到，隨着Twirla的需求和銷售額同比大幅增長，2023年運營費用也有所減少。
2024年的早期表現表明了寶貴的復甦，自推出以來，Twirla的需求達到了頂峯。
敏捷已經清償了對Perceptive Advisors的債務，隨後增加了其財務靈活性，以應對即將到來的機會。
儘管收到了納斯達克的退市通知，但敏捷的股票在場外交易市場上仍然活躍。
對《平價醫療法案》的任何修改都可以增加大約4900萬女性獲得Twirla等免費避孕產品的機會。
敏捷繼續探索融資選擇和戰略合作伙伴關係的機會，以推動進一步的業務增長。
More details: Agile Therapeutics IR
更多詳情： 敏捷療法 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。